SB creates and delivers engineered cells as medicines and treatments.
The license states that SB will have non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform.
MaxCyte will receive platform licensing fees and milestone payments.
Doug Doerfler, president and ceo of MaxCyte, said: ‘This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments.’
Story provided by StockMarketWire.com